GR3020461T3 - Lignan analog, production thereof, and hypolipidemic drug. - Google Patents

Lignan analog, production thereof, and hypolipidemic drug.

Info

Publication number
GR3020461T3
GR3020461T3 GR960401618T GR960401618T GR3020461T3 GR 3020461 T3 GR3020461 T3 GR 3020461T3 GR 960401618 T GR960401618 T GR 960401618T GR 960401618 T GR960401618 T GR 960401618T GR 3020461 T3 GR3020461 T3 GR 3020461T3
Authority
GR
Greece
Prior art keywords
lower alkyl
chem
formula
ring
substituted
Prior art date
Application number
GR960401618T
Other languages
English (en)
Inventor
Sachio Mori
Shozo Takechi
Shiro Kida
Takuji Mizui
Teruhisa Ichihashi
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of GR3020461T3 publication Critical patent/GR3020461T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/22—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one naphthalene or hydrogenated naphthalene ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
GR960401618T 1991-10-17 1996-07-04 Lignan analog, production thereof, and hypolipidemic drug. GR3020461T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29811991 1991-10-17
PCT/JP1992/001342 WO1993008155A1 (en) 1991-10-17 1992-10-15 Lignan analog, production thereof, and hypolipidemic drug

Publications (1)

Publication Number Publication Date
GR3020461T3 true GR3020461T3 (en) 1996-10-31

Family

ID=17855421

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960401618T GR3020461T3 (en) 1991-10-17 1996-07-04 Lignan analog, production thereof, and hypolipidemic drug.

Country Status (12)

Country Link
US (4) US5420333A (el)
EP (2) EP0597107B1 (el)
JP (1) JP2839805B2 (el)
KR (1) KR100252428B1 (el)
AT (2) ATE139990T1 (el)
DE (2) DE69211994T2 (el)
DK (2) DK0701991T3 (el)
ES (2) ES2129733T3 (el)
GR (1) GR3020461T3 (el)
HU (1) HU211296A9 (el)
TW (1) TW209215B (el)
WO (1) WO1993008155A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138264C (en) * 1993-04-16 2004-04-06 Sachio Mori Preparation of compounds of lignan series
FR2707980B1 (fr) * 1993-07-20 1995-09-01 Adir Nouveaux cyclohept[b]indoles et cyclooct[b]indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
AU2353095A (en) * 1994-06-22 1996-01-15 Shionogi & Co., Ltd. Process for producing phthalide compound
ID18046A (id) * 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
JP2002529409A (ja) * 1998-11-12 2002-09-10 アルテオン インコーポレーテッド グルコース及び脂質低下化合物類
KR100352269B1 (ko) * 1999-10-08 2002-09-12 한국생명공학연구원 저밀도 지질 단백질에 대해 항산화 활성을 갖는 리그난계 화합물
FR2800738B1 (fr) 1999-11-04 2002-02-08 Corning Sa Naphtopyranes ayant un substituant perfluoroalkyle en position 5, preparation et compositions et matrices (co)polymeres les renfermant
US6770024B1 (en) * 2000-03-28 2004-08-03 Stony Brook Surgical Innovations, Inc. Implantable counterpulsation cardiac assist device
TWI241195B (en) * 2000-04-10 2005-10-11 Shionogi & Co Preventive agent for bile acidic diarrhea
CA2417492A1 (en) * 2000-08-01 2003-01-28 Shionogi & Co., Ltd. Preventives or remedies for obesity or fatty liver
WO2004033411A1 (ja) * 2002-10-08 2004-04-22 Shionogi & Co., Ltd. エノンエステルの製造法
US7152611B2 (en) * 2002-12-30 2006-12-26 International Tape Partners, Llc Coated multifilament dental devices overcoated with imbedded particulate
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JP2022520121A (ja) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO170760C (no) * 1985-01-10 1992-12-02 Tanabe Seiyaku Co Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
JPS6310746A (ja) * 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
JPH0372422A (ja) * 1989-05-16 1991-03-27 Tanabe Seiyaku Co Ltd 抗脂血剤

Also Published As

Publication number Publication date
US5731455A (en) 1998-03-24
US5502216A (en) 1996-03-26
US5449814A (en) 1995-09-12
DE69211994T2 (de) 1997-02-20
EP0597107B1 (en) 1996-07-03
DK0701991T3 (da) 1999-09-13
ATE175954T1 (de) 1999-02-15
EP0597107A4 (en) 1994-02-03
ES2091488T3 (es) 1996-11-01
EP0701991A1 (en) 1996-03-20
ATE139990T1 (de) 1996-07-15
US5420333A (en) 1995-05-30
WO1993008155A1 (en) 1993-04-29
JPH05310634A (ja) 1993-11-22
JP2839805B2 (ja) 1998-12-16
KR930703236A (ko) 1993-11-29
DE69211994D1 (de) 1996-08-08
HU211296A9 (en) 1995-11-28
TW209215B (el) 1993-07-11
DK0597107T3 (da) 1996-07-29
DE69228262D1 (de) 1999-03-04
EP0701991B1 (en) 1999-01-20
ES2129733T3 (es) 1999-06-16
KR100252428B1 (ko) 2000-04-15
EP0597107A1 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
GR3020461T3 (en) Lignan analog, production thereof, and hypolipidemic drug.
HUT46899A (en) Process for production of new derivatives of 1,4-disubstituted piperasine and medical compositions containing such substances
PL307087A1 (en) Novel heterocyclic compounds for use as pharmaceuticals
DE3773546D1 (de) Naphthalenderivate, ihr herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen.
HU9300759D0 (en) Method for producing triazolo-pyridine derivatives and pharmaceutical preparatives containing said compounds as active substance
HU906402D0 (en) Process for producing tricyclic carbapeneme derivatives an pharmaceutical preparatives containing these compounds as active substance
HU9301866D0 (en) Benzoxa-condensed-ring-compounds and medical preparatives containing these compounds and processes for production of these compounds and of pharmaceutical composition
ES2055077T3 (es) Un procedimiento para preparar derivados de amida de acido carboxilico.
GB8705780D0 (en) Anticancer compounds
HUT59921A (en) Process for producing hetero-aroyl derivatives of monocyclic betalactame derivatives and pharmaceutical compositions containing them
HUT50160A (en) Process for production of derivatives of tiophene and medical compositions containing them as active substance
JPS5515408A (en) Novel mitomycin derivative and its preparation
IE781734L (en) Preparation of derivatives of benzofuran, chromene and¹isochromene
JPS5610165A (en) Novel beta-lactam compound and its production
ES2074770T3 (es) Procedimiento de preparacion de derivados de 1,3-dioxano-4,6-diona.
JPS5653654A (en) Preparation of novel aniline derivative
JPS6438063A (en) Flugimide compound and production thereof
JPS54130553A (en) 2-azetidinone derivative and its preparation
JPS5543034A (en) Thiazolidine-2-carboxylic acid derivative and agricultural and horticultural fungicide containing the same
JPS5452068A (en) 2-azetidinone derivative and its preparation
EP0555481A4 (el)
JPS6425762A (en) Cyclohexenone derivative, production thereof and herbicide
JPS54112867A (en) 1,3-dithiethane compound and its preparation
JPS5683494A (en) Production of 7alpha-alkoxycephalosporin derivative